Boston Scientific (NYSE:BSX) Stock Sold by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Boston Scientific stock on August 31st. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Stock Down 1.3%

Shares of NYSE:BSX traded down $0.57 during trading on Tuesday, hitting $43.54. 5,451,113 shares of the company’s stock traded hands, compared to its average volume of 18,739,535. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $46.97 and a 200-day moving average price of $52.24. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $105.65. The company has a market cap of $63.09 billion, a price-to-earnings ratio of 17.60, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. QRG Capital Management Inc. raised its holdings in Boston Scientific by 129.4% during the 2nd quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock worth $16,031,000 after purchasing an additional 211,855 shares during the last quarter. Andra AP fonden raised its stake in shares of Boston Scientific by 13.9% in the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock worth $8,264,000 after buying an additional 23,694 shares during the period. SkyView Investment Advisors LLC bought a new position in Boston Scientific during the 2nd quarter valued at about $107,000. Bullseye Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter worth approximately $41,000. Finally, Rench Wealth Management Inc. increased its holdings in Boston Scientific by 27.5% in the second quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider’s stock valued at $1,193,000 after buying an additional 6,033 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other news, Director David Habiger bought 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward Ludwig bought 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. Citigroup downgraded Boston Scientific from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $57.00 to $50.00 in a research report on Thursday, September 17th. Wells Fargo & Company reduced their target price on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a report on Wednesday, September 23rd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $60.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Jefferies Financial Group reduced their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. Finally, Evercore set a $65.00 price objective on Boston Scientific in a report on Monday, July 6th. Twenty-three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $70.19.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.